Patents Assigned to Bios Inc.
  • Publication number: 20250228153
    Abstract: Seed treatment systems with a mixing reservoir including a tank, a circulation mechanism positioned within the tank, and a controller coupled to the circulation mechanism, where the circulation mechanism includes a plurality of vanes configured to rotate about an axis within the tank, and where the controller is configured to mix seed treatment components within the tank in one or more mixing cycles by rotating the plurality of vanes within the tank, each mixing cycle including a first mixing operation in which the plurality of vanes rotate in a first direction about an axis for a first time period, and a second mixing operation in which the plurality of vanes rotate in a second direction about the axis opposite to the first direction for a second time period. Methods of use of the disclosed systems, e.g., for treating plant seeds, and agricultural compositions produced thereby are also provided.
    Type: Application
    Filed: June 30, 2023
    Publication date: July 17, 2025
    Applicant: Pivot Bio, Inc.
    Inventors: Keith O'BRYAN, Richard Wilson BELCHER, Matt KESTEL, Paul A. KAEB, Dominic E. MEYER, Chad Kimmelshue
  • Publication number: 20250230172
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: July 17, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • Patent number: 12349873
    Abstract: Embodiments of devices and methods for collecting gastrointestinal samples using a capsule-shaped device that is swallowed are provided.
    Type: Grant
    Filed: August 7, 2024
    Date of Patent: July 8, 2025
    Assignee: ENVIVO BIO INC
    Inventor: Tidhar Dari Shalon
  • Patent number: 12345677
    Abstract: A system and apparatus for direct or indirect target substance signal measurement include an integrated circuit with an array of 2D FETs with corresponding 2D transistor channels and a gate area for receiving a volume of liquid with one or more chemical or biological target substances, a conductive source electrically coupled to a first end of the 2D transistor channel, a conductive drain electrically coupled to a second end of the 2D transistor channel, a ceramic coating over the conductive source and the conductive drain and a thin film layer of synthetic biopolymer specific binding agents is adsorbed to the top surface of the 2D transistor channel. Methods for the system and apparatus and for selecting the synthetic biopolymer specific binding agents based on absorptivity are disclosed.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: July 1, 2025
    Assignee: Cardea Bio, Inc.
    Inventors: Kiana Aran, Brett Goldsmith, Alexander Kane, Regis Peytavi
  • Publication number: 20250206826
    Abstract: The present disclosure relates to a method of depleting or reducing the numbers of disease-causing agents including host cells, or host cells products, microbes or their products in a human subject upon administration of molecule that causes targeted phagocytosis and comprises a binding domain that binds a specific phagocytotic receptor, such as Dectin-1, and a binding domain that binds a specific disease-causing agent. In a specific embodiment, a method of the disclosure depletes or reduces the number of disease-causing agents in tissues, blood, or bone marrow by targeted phagocytosis.
    Type: Application
    Filed: December 10, 2024
    Publication date: June 26, 2025
    Applicant: Dren Bio, Inc.
    Inventors: Panagiotis FOTAKIS, Chanty Mariategue CHAN, Ruo Shi SHI, Adam Lewis SALLES, Nenad TOMASEVIC
  • Publication number: 20250205282
    Abstract: The method entails modification of non-malignant cells for transplantation or therapy to avoid recognition and attack by monoclonal antibodies and antibody-derived therapeutics. Many therapies that use monoclonal antibodies or antibody-derived therapeutics not only bind to the intended target epitope on malignant cells, but also to the same target epitope on healthy non-malignant cells that express the target antigen. This phenomenon is termed on-target off-tumor effect. This can cause rejection, immune cell attack or opsonization of non-malignant cells, which in turn can cause severe side effects which often hampers the therapeutic effect. Similarly, cytokines in cytokine therapy can bind to receptors on bystander cells and cause unintended effects.
    Type: Application
    Filed: March 28, 2023
    Publication date: June 26, 2025
    Applicant: VyGen-Bio, Inc.
    Inventors: Arnika WAGNER, Evren ALICI
  • Patent number: 12329726
    Abstract: Biomarkers for assessing the efficacy of prophylactic treatments of stress-induced affective disorders are provided.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: June 17, 2025
    Assignees: The Trustees of Columbia University in the City of New York, BPG BIO, INC, The Research Foundation for Mental Hygiene, Inc
    Inventors: Josephine Cecelia McGowan, Christine Ann Denny, Michael Kiebish
  • Patent number: 12331005
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: August 7, 2024
    Date of Patent: June 17, 2025
    Assignee: TRANSLATE BIO, INC.
    Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
  • Patent number: 12318275
    Abstract: A hybrid medical device that can aid in reconstructive or augmentative surgery of the breast is disclosed. The device can utilize a suitable biological collagen tissue matrix combined with a synthetic material, for example, that can impart a high initial strength to the repair site while permitting proper healing and revitalization of the implanted device.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: June 3, 2025
    Assignee: Tela Bio, Inc.
    Inventors: E. Skott Greenhalgh, John-Paul Romano
  • Patent number: 12319933
    Abstract: Culture supplement compositions for producing enhanced cellular agriculture products include a formulation including at least one enzyme in a carrier. As embodied herein, the formulation can be configured to adjust production of a base cellular agriculture product to produce an enhanced cellular agriculture product without reducing or inhibiting biomass production or cellular viability compared to the base cellular agriculture product. Furthermore, or as an alternative, the culture supplement composition can further include, in the carrier, at least one of a substrate or an additive. Cellular agriculture products made using the compositions are also provided.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: June 3, 2025
    Assignee: ALCHEME BIO INC.
    Inventor: Vanessa Small
  • Patent number: 12320880
    Abstract: During operation, a computer system may acquire magnetic resonance (MR) signals associated with a sample from a measurement device or memory. Then, the computer system may access a predetermined set of coil magnetic field basis vectors associated with a surface surrounding the sample, where coil sensitivities of coils in the measurement device are represented by weighted superpositions of the predetermined set of coil magnetic field basis vectors using coefficients, and where the predetermined coil magnetic field basis vectors are solutions to Maxwell's equations. Next, the computer system may solve, on a voxel-by-voxel basis for voxels associated with the sample, a nonlinear optimization problem for MR information associated with the sample and the coefficients using: a forward model that uses the MR information as inputs and simulates response physics of the sample, the MR signals and the predetermined set of coil magnetic field basis vectors.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: June 3, 2025
    Assignee: Q Bio, Inc.
    Inventors: Matteo Alessandro Francavilla, Jorge Fernandez Villena, Stamatios Lefkimmiatis, Athanasios Polymeridis, Doruk Tayli
  • Patent number: 12314768
    Abstract: System and method for updating a computational workflow and processing input information sets in accordance with the updated computational workflows. Exemplary implementations may: store workflow definitions for computational workflows, computational modules, output information sets, and/or other information; receive update information corresponding to the first computational workflow; update the first workflow definition in accordance with the update information to generate an updated workflow definition for the first computational workflow; process the first input information set in accordance with the updated workflow definition to generate a second output information set; determine variance information documenting variation between the first output information set and the second output information set; output one or more of the second output information set or the variance information; and/or other exemplary implementations.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: May 27, 2025
    Assignee: Form Bio Inc.
    Inventors: Andrew Busey, Brandi Lynn Cantarel, Douglas James Daniels, Jr.
  • Publication number: 20250161221
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Application
    Filed: January 17, 2025
    Publication date: May 22, 2025
    Applicant: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • Publication number: 20250161286
    Abstract: The disclosure relates to compositions and methods of using a pomalidomide derivative that exhibits improved pharmacological effects as compared to pomalidomide for treating brain diseases. The pomalidomide derivative exhibits excellent binding to cereblon, has almost no cytotoxicity, is unlikely to cause teratogenic adverse effects, can control TNF-? expression, exhibits excellent in vivo pharmacokinetic stability while suppressing oxidative stress, ameliorates a decrease in motor function which is a symptom of Parkinson's disease, and increases tyrosine hydroxylase expression which is reduced by Parkinson's disease, and thus can be used for preventing or treating brain diseases such as Parkinson's disease.
    Type: Application
    Filed: February 24, 2023
    Publication date: May 22, 2025
    Applicant: AEVIS BIO, INC.
    Inventors: Dong Seok KIM, Inho HWANG, Sun KIM
  • Publication number: 20250145718
    Abstract: The present disclosure provides a polynucleotide encoding the anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.
    Type: Application
    Filed: January 7, 2025
    Publication date: May 8, 2025
    Applicants: ABL BIO INC., I-MAB BIOPHARMA US LIMITED
    Inventors: Eunyoung PARK, Yangsoon LEE, Hyejin CHUNG, Eunsil SUNG, Jiseon YOO, Minji PARK, Yong-Gyu SON, Hyoju CHOI, Eunjung KIM, Jaeho JUNG, Weon-Kyoo YOU, Sang Hoon LEE, Lei FANG, Wenqing JIANG
  • Publication number: 20250145544
    Abstract: The present disclosure provides water-soluble film packages composed of a water-soluble film, where the packages include: one or more compartment(s) including dehydrated microbes. The disclosure further provides methods of production of the water-soluble film packages, and methods of application thereof. The water-soluble packages of the disclosure enable convenient and accurate application of microbial dry powders to plants, promote uniform dispersion of powdered microbes, enhance microbial shelf life, and enhance the survival of microbes on seed, while being environmentally sustainable.
    Type: Application
    Filed: February 9, 2023
    Publication date: May 8, 2025
    Applicant: Pivot Bio, Inc.
    Inventors: Scott Alan STROBEL, Farzaneh REZAEI, Ernest SANDERS, Richard BROGLIE
  • Publication number: 20250144201
    Abstract: A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.
    Type: Application
    Filed: January 12, 2025
    Publication date: May 8, 2025
    Applicant: Prime Bio, Inc.
    Inventors: Bal Ram Singh, Raj Kumar, Kruti Patel
  • Patent number: 12290074
    Abstract: The present disclosure provides non-intergeneric remodeled microbes that are able to fix atmospheric nitrogen and deliver such to plants in a targeted, efficient, and environmentally sustainable manner. The utilization of the taught microbial products will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived nitrogen fertilizer. The remodeled microbes taught herein are able to be combined with leading agricultural chemistry and elite germplasm. Furthermore, the disclosure provides seed treatments comprising remodeled microbes.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: May 6, 2025
    Assignee: Pivot Bio, Inc.
    Inventors: Mark Reisinger, Ernest Sanders, Richard Broglie, Karsten Temme
  • Patent number: 12291722
    Abstract: The invention provides compositions and methods for manufacturing adoptive cell therapies. In particular embodiments, the invention provides methods of harvesting populations of cells, isolating and activating PBMCs, expanding T cells, and administering the T cell therapeutic to a subject in need thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 6, 2025
    Assignee: 2seventy bio, Inc.
    Inventors: Richard Morgan, Kevin Friedman, Dawn Maier
  • Patent number: 12291529
    Abstract: The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
    Type: Grant
    Filed: July 2, 2024
    Date of Patent: May 6, 2025
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Wei Huang, Hui Lei, Chunliang Lu, Haizhen Zhang